SUBSTITUTED PORPHYRINS

• US 20070197496A1
• Filed: 06/16/2006
• Published: 08/23/2007
• Est. Priority Date: 01/25/1999
• Status: Active Grant

• Current Assignee: Aeolus Sciences Incorporated, Duke University, National Jewish Health
• Original Assignee: National Jewish Health
• Inventors: Fridovich, Irwin, Batinic-Haberle, Ines, Day, Brian, Crapo, James, Kitchen, Douglas, Trova, Michael, Gauuan, Polvina
• Granted Patent: US 7,820,644 B2
• Time in Patent Office: Days
• US Class Current: 514/185
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 487/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C09B 47/00 Porphines; Azaporphines non-dyeing compounds C07D487/22

Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Claims

1-33. -33. (canceled)

34. A method of treating a pathological condition of a patient resulting from degradation of NO′

or a biologically active form thereof, comprising administering to said patient an effective amount of a compound of formula

35. The method according to claim 34 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

36. The method according to claim 35 wherein said compound is complexed with manganese.

37. A method of treating a patient for an inflammatory disease comprising administering to said patient an effective amount of a compound of formula

38. The method according to claim 37 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

39. The method according to claim 38 wherein said compound is complexed with manganese.

40. The method according to claim 37 wherein said inflammatory disease is an inflammatory lung disease.

41. The method according to claim 40 wherein said inflammatory lung disease is bronchopulmonary disease.

42. The method according to claim 40 wherein said inflammatory lung disease is asthma.

43. The method according to claim 40 wherein said inflammatory lung disease is pulmonary fibrosis.

44. A method of treating a patient for an ischemic reperfusion injury comprising administering to said patient an effective amount of a compound of formula

45. The method according to claim 44 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

46. The method according to claim 45 wherein said compound is complexed with manganese.

47. The method according to claim 44 wherein said ischemic reperfusion injury results from a stroke.